Claims for Patent: 9,789,210

Summary for Patent: 9,789,210

Title:	Methods for making ultrasound contrast agents
Abstract:	Provided herein are improved methods for preparing phospholipid formulations including phospholipid UCA formulations.
Inventor(s):	Robinson; Simon P. (Stow, MA), Siegler; Robert W. (Chelmsford, MA), Nguyen; Nhung Tuyet (Westford, MA), Onthank; David C. (Groton, MA), Anklekar; Tarakeshwar Vishwanath (Billerica, MA), Van Kirk; Charles Chester (Beverly, MA)
Assignee:	Lantheus Medical Imaging, Inc. (North Billerica, MA)
Application Number:	15/461,469
Patent Claims:	1. A method of ultrasound contrast imaging a subject comprising (a) activating a phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid suspension comprises a phospholipid solution having DPPA, DPPC and MPEG5000-DPPE, in a mole % ratio of 10 to 82 to 8 (10:82:8), in propylene glycol, the MPEG5000-DPPE selected as having a calcium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a calcium concentration of less than 0.7 ppm, (b) administering the lipid-encapsulated gas microspheres to a subject, and (c) obtaining an ultrasound image of the subject. 2. A method of ultrasound contrast imaging a subject comprising (a) activating a phospholipid suspension with a perfluorocarbon gas to form lipid-encapsulated gas microspheres, wherein the phospholipid suspension comprises a phospholipid solution made under a methanol and toluene free condition and a methyl t-butyl ether free condition and having DPPA, DPPC and MPEG5000-DPPE, in a mole % ratio of 10 to 82 to 8 (10:82:8), in propylene glycol, the MPEG5000-DPPE having a calcium concentration of less than 115 parts per million (ppm), and the phospholipid solution having a calcium concentration of less than 0.7 ppm, (b) administering the lipid-encapsulated gas microspheres to a subject, and (c) obtaining an ultrasound image of the subject. 3. The method of claim 2, wherein the calcium concentration is determined using atomic absorption spectroscopy. 4. The method of claim 1, wherein the calcium concentration is determined using atomic absorption spectroscopy. 5. The method of claim 1, wherein the calcium concentration is determined using inductively coupled plasma mass spectrometry (ICP-MS). 6. The method of claim 2, wherein the calcium concentration is determined using inductively coupled plasma-mass spectrometry (ICP-MS). 7. The method of claim 1, wherein the calcium concentration of DPPA is less than 780 ppm, the calcium concentration of DPPC is less than 90 ppm, and the calcium concentration of propylene glycol is less than 0.7 ppm. 8. The method of claim 2, wherein the calcium concentration of DPPA is less than 780 ppm, the calcium concentration of DPPC is less than 90 ppm, and the calcium concentration of propylene glycol is less than 0.7 ppm. 9. The method of claim 2, wherein MPEG5000-DPPE is selected as having a calcium concentration of less than 115 ppm.